New Leaf Venture Partners
New Leaf Venture Partners is a venture capital firm focused on investments in healthcare technology companies.
Business Model:
Revenue: $18M
Employees: 2-10
Rankings
Industries / Tags:
Detailed New Leaf Venture Partners Information
Geographic Data
Address: Times Square Tower , 7 Times Square
City: New York
State: NY
Zip: 10036
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$400M
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies. The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, the venture capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.
Contact Phone:
+16468716400
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2021 | Cleerly | Series B | 0 |
| 8/2020 | ReViral | Series C | 0 |
| 9/2019 | Edgewise Therapeutics | Series B | 50M |
| 10/2012 | ReShape Lifesciences | Post-IPO Equity | 15M |
| 5/2018 | IRLAB Therapeutics | Series A | 15.8M |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 11/2006 | Concert Pharmaceuticals | Series B | 48.5M |
| 10/2009 | Direct Flow Medical | Series C | 40M |
| 11/2012 | MEI Pharma | Post-IPO Equity | 27.5M |
| 3/2012 | GluMetrics | Venture Round | 13.3M |
| 6/2011 | Aviir | Venture Round | 3M |
| 5/2007 | Interlace Medical | Series B | 3M |
| 7/2008 | Interlace Medical | Series B | 7M |
| 4/2013 | Pearl Therapeutics | Venture Round | 41.7M |
| 10/2020 | TigerConnect | Series D | 0 |
| 9/2007 | Pearl Therapeutics | Series A | 15.5M |
| 11/2012 | Pearl Therapeutics | Series D | 65M |
| 10/2007 | Relypsa | Series A | 33M |
| 8/2019 | Renovacor | Series A | 11M |
| 5/2016 | AVEO Oncology | Post-IPO Equity | 17M |
| 6/2015 | Advanced Cell Diagnostics | Series C | 22M |
| 7/2018 | Alector | Series E | 133M |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 5/2016 | Aptinyx | Series A | 0 |
| 9/2013 | Catalyst Pharmaceuticals Partners | Post-IPO Equity | 15.1M |
| 11/2006 | Aesthetic Sciences | Series A | 6M |
| 8/2020 | Saniona | Post-IPO Equity | 0 |
| 11/2007 | Oriel Therapeutics | Venture Round | 26.5M |
| 6/2020 | BrightInsight | Series B | 40M |
| 4/2018 | Rallybio | Series A | 37M |
| 2/2011 | Chimerix | Series F | 45M |
| 10/2010 | Convergence Pharmaceuticals | Series A | 35.4M |
| 12/2009 | Afferent Pharmaceuticals | Series A | 23M |
| 9/2019 | BrightInsight | Series A | 25M |
| 8/2015 | ReShape Lifesciences | Post-IPO Equity | 38M |
| 6/2016 | Kit Check | Series C | 0 |
| 10/2013 | Versartis | Series D | 0 |
| 7/2010 | Artisan Pharma | Series C | 0 |
| 4/2013 | iRhythm Technologies | Series D | 16M |
| 1/2012 | iRhythm Technologies | Private Equity Round | 12.2M |
| 5/2011 | iRhythm Technologies | Series C | 15M |
| 4/2020 | Rallybio | Series B | 0 |
| 6/2013 | Kit Check | Series A | 10.4M |
| 6/2012 | Awarepoint | Venture Round | 14M |
| 7/2015 | Afferent Pharmaceuticals | Series C | 55M |
| 10/2010 | WorldHeart | Venture Round | 25.3M |
| 1/2012 | Access Closure | Venture Round | 0 |
| 2/2007 | Visiogen | Venture Round | 24M |
| 9/2010 | Intarcia Therapeutics | Debt Financing | 5M |
| 10/2009 | Neuronetics | Series D | 0 |
| 10/2012 | Access Closure | Venture Round | 0 |
| 3/2011 | Synageva BioPharma | Venture Round | 0 |
| 6/2007 | BioRelix | Series A | 25.8M |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 2/2010 | Tioga Pharmaceuticals | Venture Round | 18M |
| 2/2009 | ReShape Medical | Series B | 20M |
| 3/2021 | BrightInsight | Series C | 101M |
| 1/2016 | AiCure | Series A | 12.3M |
| 8/2009 | SchoolCare | Series G | 14.4M |
| 10/2012 | Pearl Therapeutics | Private Equity Round | 23.3M |
| 6/2012 | Oxford Immunotec | Equity | 28M |
| 6/2009 | VaxInnate | Series D | 30M |
| 10/2010 | Pearl Therapeutics | Series C | 69M |
| 10/2009 | Synageva BioPharma | Series F | 0 |
| 4/2014 | Intarcia Therapeutics | Venture Round | 0 |
| 9/2006 | Artisan Pharma | Series A | 39M |
| 7/2009 | Presidio Pharmaceuticals | Venture Round | 27M |
| 12/2017 | Aptinyx | Series B | 70M |
| 7/2013 | Karyopharm Therapeutics | Series B | 19M |
| 5/2018 | Neurana Pharmaceuticals | Series A | 0 |
| 7/2008 | Pearl Therapeutics | Series A | 18M |
| 1/2006 | Tioga Pharmaceuticals | Series A | 24M |
| 9/2010 | Relypsa | Series B | 70M |
| 10/2015 | Arvinas | Series B | 41.6M |
| 8/2015 | Principia Biopharma | Series B | 15.3M |
| 11/2021 | Asimily | Venture Round | 0 |
| 7/2012 | Vifor Pharma | Private Equity Round | 0 |
| 4/2013 | Treato | Series B | 14.5M |
| 4/2014 | Principia Biopharma | Series B | 50M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 8/2022 | Arine | Series B | 0 |
| 10/2012 | Relypsa | Venture Round | 2.6M |
| 8/2011 | Relypsa | Series B | 70.1M |
| 3/2012 | BioRelix | Venture Round | 2.6M |
| 9/2011 | CardioKinetix | Series E | 21M |
| 2/2010 | Pearl Therapeutics | Series C | 15M |
| 1/2018 | Braeburn | Debt Financing | 0 |
| 5/2014 | QPID Health | Series B | 12.3M |
| 9/2019 | Passage Bio | Series B | 110M |
| 2/2010 | Intrinsic Therapeutics | Venture Round | 18M |
| 9/2015 | Deciphera Pharmaceuticals | Series B | 75M |
| 4/2015 | Dimension Therapeutics | Series B | 65M |
| 10/2018 | CuraSen Therapeutics | Series A | 54.5M |
| 6/2016 | CRISPR Therapeutics | Series B | 0 |
| 10/2007 | Direct Flow Medical | Series B | 27M |
| 6/2015 | Cogent Biosciences | Series B | 65M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 11/2012 | Advanced Cell Diagnostics | Series B | 12M |
| 3/2010 | Access Closure | Venture Round | 10M |
| 8/2018 | ReViral | Series B | 0 |
| 2/2011 | Spiracur | Series C | 35M |
| 11/2015 | ObsEva | Series B | 60M |
| 11/2012 | Intarcia Therapeutics | Debt Financing | 50M |
| 2/2011 | Spine Wave | Series E | 17.5M |
| 11/2012 | Intarcia Therapeutics | Venture Round | 160M |
| 6/2010 | Altura Medical | Series A | 20M |
| 10/2009 | Aviir | Venture Round | 1M |
| 8/2012 | Vifor Pharma | Series C | 0 |
| 12/2008 | Aviir | Venture Round | 7.8M |
| 6/2013 | Aviir | Series B | 10M |
| 1/2008 | Sopherion Therapeutics | Venture Round | 0 |
| 1/2010 | Aviir | Venture Round | 4.2M |
| 9/2007 | Aviir | Series B | 11.3M |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 12/2011 | Aviir | Venture Round | 10M |
| 8/2007 | ReShape Lifesciences | Series A | 3M |
| 4/2008 | IlluminOss Medical | Series B | 11M |
| 3/2010 | Aureon Laboratories | Series C | - |
| 3/2007 | ProteoGenix | Series B | 20M |
| 9/2012 | Karus Therapeutics | Series B | 7.6M |
| 10/2006 | VaxInnate | Series C | 40M |
| 10/2012 | Principia Biopharma | Series A | 12.5M |
| 6/2016 | Bluesight | Series C | 20.4M |
| 1/2015 | Bluesight | Series B | 12M |
| 1/2014 | TigerConnect | Series B | 23M |
| 3/2008 | Spiration | Series G | 18.5M |
| 4/2018 | Arvinas | Series C | 55M |
| 7/2009 | Interlace Medical | Series C | 20.5M |
| 9/2017 | Truveris | Series D | 25M |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 3/2013 | CardioKinetix | Series E | 23M |
| 12/2018 | Bellus Health | Post-IPO Equity | 26M |
| 5/2017 | Harpoon Therapeutics | Series B | 45M |
| 5/2011 | Neuronetics | Series E | 30M |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 6/2017 | Neuronetics | Series G | 0 |
| 4/2015 | Neuronetics | Series F | 0 |
| 3/2007 | Intarcia Therapeutics | Venture Round | 50M |
| 4/2010 | Aureon Laboratories | Series D | 7M |
| 7/2013 | Versartis | Series C | 0 |
| 4/2008 | Concert Pharmaceuticals | Series C | 0 |
| 4/2008 | Stromedix | Series B | 25M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 4/2006 | Spiration | Series F | 13.4M |
| 8/2008 | GluMetrics | Series C | 20.1M |
| 4/2012 | Direct Flow Medical | Venture Round | 0 |
| 2/2009 | ReShape Lifesciences | Post-IPO Equity | 20M |
| 1/2013 | Versartis | Series C | 0 |
| 4/2018 | Kyruus | Corporate Round | 0 |
| 9/2015 | Kyruus | Series C | 25M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 11/2019 | AiCure | Series C | 24.5M |
| 6/2009 | Spiracur | Series B | 20.3M |
| 8/2015 | Wave Life Sciences | Series B | 66M |
| 5/2021 | Akili Interactive Labs | Series D | 0 |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 11/2018 | Harpoon Therapeutics | Series C | 70M |
| 7/2020 | Glympse Bio | Series B | 46.7M |
| 11/2017 | AiCure | Series B | 15M |
| 2/2014 | Versartis | Series E | 55M |
| 1/2013 | GluMetrics | Debt Financing | 5.6M |
| 12/2014 | CardioKinetix | Series F | 0 |
| 8/2008 | ProteoGenix | Series B | 8M |
| 2/2013 | Aviir | Series B | 10M |
| 8/2006 | Interlace Medical | Series A | 750k |
| 10/2012 | Presidio Pharmaceuticals | Venture Round | 8M |
| 5/2010 | Oxford Immunotec | Series D | 26M |
| 3/2018 | Technology Will Save Us | Series A | 0 |
| 2/2011 | Versartis | Series B | 21M |
| 2/2012 | Truveris | Series B | 10M |
| 4/2015 | Edge Therapeutics | Series C | 56M |
| 6/2013 | Bluesight | Series A | 10.4M |
| 5/2009 | Visiogen | Series D | 40M |
| 8/2019 | Qlaris Bio | Series A | 8.2M |
| 6/2017 | Deciphera Pharmaceuticals | Series C | 52M |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 11/2021 | Asimily | Venture Round | 0 |
| 8/2021 | Dice Therapeutics | Series C | 0 |
| 6/2021 | Cleerly | Series B | 0 |
| 5/2021 | Akili Interactive Labs | Series D | 0 |
| 3/2021 | BrightInsight | Series C | 0 |
| 1/2021 | Dice Therapeutics | Series C | 0 |
| 10/2020 | TigerConnect | Series D | 0 |
| 8/2020 | ReViral | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
